Reviva Net Income From Continuing Ops from 2010 to 2024

RVPHW Stock  USD 0.21  0.04  23.53%   
Reviva Pharmaceuticals Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. During the period from 2010 to 2024, Reviva Pharmaceuticals Net Loss regression line of quarterly data had r-squared of  0.56 and coefficient of variation of (169.04). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-39.3 M
Current Value
-37.3 M
Quarterly Volatility
13.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 523.9 K or Interest Income of 523.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.36. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Reviva Pharmaceuticals Holdings over the last few years. It is Reviva Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Reviva Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(8,111,434)
Coefficient Of Variation(169.04)
Mean Deviation10,263,209
Median(846,832)
Standard Deviation13,711,615
Sample Variance188T
Range38.4M
R-Value(0.75)
Mean Square Error89T
R-Squared0.56
Significance0
Slope(2,295,046)
Total Sum of Squares2632.1T

Reviva Net Income From Continuing Ops History

2024-37.3 M
2023-39.3 M
2022-24.3 M
2021-8.5 M
2020-3.8 M

About Reviva Pharmaceuticals Financial Statements

Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-39.3 M-37.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.